key: cord-0744688-8by10mkf
authors: Martin, Jennifer; Head, Richard
title: A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPURPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID‐19
date: 2020-09-22
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14551
sha: 91ee0c120f828c51560581b582770e542366d73c
doc_id: 744688
cord_uid: 8by10mkf

With any new disease a framework for development of preventative or treatment therapeutics is key; the absence of such in COVID‐19 has enabled ineffective and potentially unsafe treatments to be taken up by Governments and clinicians desperate to have options for patients. As we still have few therapies and nil vaccines yet available, the void of a clear framework for research and practice is increasingly clear. We describe a framework that has been used to prioritise therapeutic research in previous pandemics which could be used to progress clinical pharmacology and therapeutics research in COVID‐19. This is particularly relevant as discussion has already moved on from antiviral therapeutics, to delineating the treatment of the host from treatment and elimination of the infective agent. Focussing on the host brings together three concepts; host treatment, the damage response framework and therapeutic repurposing. The integration of these three areas play to the traditional strength of pharmaceuticals in providing a period of stabilization to permit time for the development of novel anti‐viral drugs and vaccines. In integrating approaches to repurposing, host treatment and damage response we identified three key properties that a potentially effective repurposed drug must possess by way of a framework. There must be homology i.e. the same or similar relation, with the pathogenesis of the disease, ideally targeted to the conserved pathophysiological outcomes of the viral attack, have a defined locus within the spectrum from prevention to severe disease and draw upon the historical dose and safety experience of the repurposed drug. To illustrate, we have mapped therapeutics that impact upon a key dysregulated pathway in COVID‐19 ‐ the renin angiotensin system‐ using this approach. Collectively this type of analysis reveals the importance of existing data (repurposed information and administrative observational) and the importance of the details of the known pathophysiological response to viruses in approaches to treating the host.

With any new disease a framework for development of preventative or treatment therapeutics is key; the absence of such in COVID-19 has enabled ineffective and potentially unsafe treatments to be taken up by Governments and clinicians desperate to have options for patients. As we still have few therapies and nil vaccines yet available, the void of a clear framework for research and practice is increasingly clear. We describe a framework that has been used to prioritise therapeutic research in previous pandemics which could be used to progress clinical pharmacology and therapeutics research in COVID-19. This is particularly relevant as discussion has already moved on from antiviral therapeutics, to delineating the treatment of the host from treatment and elimination of the infective agent.

Focussing on the host brings together three concepts; host treatment, the damage response framework and therapeutic repurposing. The integration of these three areas play to the traditional strength of pharmaceuticals in providing a period of stabilization to permit time for the development of novel anti-viral drugs and vaccines. In integrating approaches to repurposing, host treatment and damage response we identified three key properties that a potentially effective repurposed drug must possess by way of a framework. There must be homology i.e. the same or similar relation, with the pathogenesis of the disease, ideally targeted to the conserved pathophysiological outcomes of the viral attack, have a defined locus within the spectrum from prevention to severe disease and draw upon the historical dose and safety experience of the repurposed drug. To illustrate, we have mapped therapeutics that impact upon a key dysregulated pathway in COVID-19 -the renin angiotensin system-using this approach. Collectively this type of analysis reveals the importance of existing data (repurposed information and administrative observational) and the importance of the details of the known pathophysiological response to viruses in approaches to treating the host.

Recently Sanders et al. (1) have highlighted both the fact that no therapies for treating were available at their time of writing and yet the need to have high quality evidence readily available in a pandemic. In a solution to this problem, we note there exists the potential confluence of two approaches that may prove beneficial in this pandemic setting. The first seeking agents that treat the host, not necessarily the virus, and building on the pioneering studies of David Fedson in this field (2) (3) (4) (5) ; the second, the concept of repurposing existing therapeutics for new indications.

Both concepts are enshrined in pharmacological principles.

In this Review we have below explored these concepts and provide a potential path for efficient evaluation of candidate drugs using inhibitors of the Renin Angiotensin System (RAS) as an example.

One of the key values of therapeutics is their potential in stabilizing patients prior to subsequent interventions or their use as adjuncts to those interventions. The settings where this may occur are varied and include response to traumatic injury to control damage, treat infection and alleviate pain.

Other notable examples include the development of anaesthesiology and sedation to enable the performance of surgery and complex procedures, as well the development of non-depolarising neuromuscular-blocking drugs as adjuncts to those surgical procedures and of adjunctive chemotherapy to improve quality of life and survival time. Of particular interest in this pandemic context has been the centuries old development of agents to promote survival with infections.

Historically the focus was upon identifying agents that would kill the invading species and not damage the host. In more recent times the focus has moved to delineating the treatment of the host from treatment and elimination of the infective agent.

In 2016, Fedson highlighted the treating of the host concept, based upon an understanding that a beneficial clinical phenotype has been observed with a treatment and this can be employed for the purpose of treating the host (3). This was done in the context of emerging virus diseases, and more recently in the context of severe COVID-19 infection (5) . Consistent with this view Yan et al. (6) drew attention to the need for agents to alleviate H5N1 virus-induced lung injury due to the limited strategies for treating influenza virus infection.

The concept of treating the host is entirely complementary to opportunities arising in the area of drug repurposing that we have highlighted recently (7) . In the case of COVID-19 disease this would mean identifying drugs that are focused, not on the elimination of the virus, but upon the survival of the patient with severe COVID-19 disease. This includes drugs approved for other indications that have the beneficial phenotype for treating severe COVID-19 disease. The fundamental advantages of this approach are; firstly, to buy needed time for the concurrent development of anti-viral or vaccines, secondly to provide health authorities a treatment insurance as they begin to release the public from social isolation. We have highlighted this key aspect recently in the context of COVID-19 disease (8) supported by a recent UK study showing a mortality benefit of dexamethasone in patients undergoing invasive mechanical ventilation and among those receiving oxygen without invasive mechanical ventilation. Note that data suggested dexamethasone might be harmful if used earlier, confirming the need for clinical trials to understand not just the dose, but pathophysiology, to guide the timing of therapies (9); Figure 1 .

However ,this very obvious but distinct suite of proposed solutions to reduce the morbidity and mortality from COVID-19 has the potential risk of cutting across fixed interests and previously effective methods of succeeding in grant funding rounds, including silos of 'ology disciplines, and pressures from news cycles and campaigning for ineffective policies.

What is needed is the appropriate framework for treating the host, a strategy for positioning this approach, and then implementation.

A framework for treating the host with repurposed drugs.

Treating the host in COVID-19 brings together two key pharmacological principals. The first involves the understanding of how a proposed therapeutic agent integrates within the pathogenic response.

This approach thus involves understanding initially the integration of the host into the consequences of viral pathogenesis. This relationship has been well described for microbial pathogenesis in the Damage-Response Framework (DRF) in infectious diseases (10) . The damaging host factors described in this microbial model, namely cytokine release (storm), chemical mediators signalling, oxygen radical production and immune complexes leading to aberrant inflammation are not specific and in fact apply equally to viruses such as influenza and the current COVID-19 disease.

The second principal involves the appropriate use of therapeutics approved for one indication but used effectively in a different setting within the DRF. Approaches used for drug repurposing, the challenges and ways in which these challenges may be tackled have been described recently in detail (11) . The application to COVID-19 involves identification of drugs that in a new indication, in the correct dosage for the new disease have a substantial impact on the consequences of infection in the host. This article is protected by copyright. All rights reserved. Exploration of the treating the host concept, using repurposed agents acting on the renin angiotensin system -ATC C09.

From the preceding discussion, a framework for treating the host and repurposing can be employed to explore the eligibility of drugs that influence the renin angiotensin system as candidates for clinical trials. In particular to identify what is known about these agents in regard to: 1) Pathogenesis 2) Target homology of COVID-19 3) Prevention/ Treatment and 4) Dose-Response curve in relation to safety.

To treat the host requires an understanding of the physiology of this response to that condition (in this case . In addition, knowledge is needed of chemical, structural and immunological homology with the novel action of the repurposed drug and the molecular events that drive the consequences of viral pathogenesis in COVID-19 disease. As the main causes of death in COVID-19 are pulmonary vasoconstriction, pulmonary oedema, thrombosis, and fibrosis, a focus on RAS inhibition, a key driver of (a) Pulmonary Complications -pro-thrombotic and inflammation in the lung (b) Innate Immune Response and (c) Vascular Response -vasoconstriction, inflammation and coagulation is key.

During early 2020, an enormous amount was written on the pathogenesis of COVID-19, including comprehensive summary review articles with strong emphasis on pulmonary pathophysiology in this condition (12) (13) (14) , inter alia). The relationship between the dysregulation of the pulmonary RAS and the progression to severe acute respiratory syndrome (SARS) including the intermediate stages of

infections and pneumonia has been discussed at length. By way of summary the fundamental initiation is the role of ACE2 as the receptor for SARS coronavirus infection (15) . It is the impact of this initiation that drives a pulmonary dysregulation of the finely balanced RAS. This balance involves the generation of angiotensin II by ACE and the inactivation of that peptide by ACE2. The functional role of ACE2, its catalytic product angiotensin1-7 and the MAS receptor are the counterbalance moieties for angiotensin II and its AT1R receptor (12) . The interaction of angiotensin 1-7 with MAS receptors promotes an anti-inflammatory response, vasodilation an anti-fibrotic response and is seen as protective. Down regulation of ACE2 in acute lung injury models with SARSCoV infection supports a protective role for RAS blockade in this form of pulmonary infection (12) . The core hypothesis is that a dysregulated RAS is core to the pathophysiology of COVID-19 driven lung damage and acute respiratory distress syndrome (16) . This builds upon much earlier experimentation showing the angiotensin II receptor blocker (ARB) losartan could effectively reduce acute lung injury induced by SARS-CoV (17) .The summary statement is most apt: "Therefore, in acute lung injury, ACE, Ang II, and AT1R function as lung-injury-promoting factors, while ACE2 protects from lung injury" (18) . References 13, 17, 33,34,39 also detail this pathophysiological pathway in significant detail.

It follows that from a repurposing standpoint that there exists a strong target homology with agents that promote RAS inhibition and the pathogenesis of COVID-19 disease in the lung in terms of pathophysiology and pharmacology. This article is protected by copyright. All rights reserved.

1b. Innate Immune Response. Angiotensin II, via activation of the AT1R receptor, is pivotal in modulating immune responses. A key immune cell involved with the RAS pathway -mast cell -is found in the submucosal tissue in human bronchi in the upper and lower respiratory tree (19) . Mast cells rapidly recognise pathogens and mount an immune response that includes plasma extravasation, immunological and cytokine modulation, leukocyte recruitment and ultimately cellular inflammation (20) . What is critical is the role of mast cells in the bronchi in the release of renin and the initiation of the production of the angiotensin II that acts through AT1R receptors (19) .

Moreover, in an experimental model of hypersensitivity, anaphylactic mast cell degranulation has been shown to result in angiotensin bronchoconstriction (19) . Of significance is the observation that mast cell chymase can generate angiotensin II independently of ACE activity (21) , the salient point being that ACE is membrane bound and chymase upon release moves within interstitial spaces. ACE also modulates macrophage and neutrophil function in its role in the innate and adaptive response (22) .

Angiotensin II mediates its pro-inflammatory responses by signalling through AT1R receptor.

These responses include, leukocyte recruitment, increased production of reactive oxygen species by receptor (AT1R) activation of NADPH oxidase, contributing to inflammation and the stimulation of (19) . Moreover, in an animal model of hypersensitivity mast cell degranulation was associated with angiotensin II mediated constriction, inhibited with an AT1R blocker or an inhibitor of renin (19) . From a repurposing standpoint that there exists a strong target similarlity with agents that promote RAS inhibition and the modulation of innate immune responses in the lung.

This article is protected by copyright. All rights reserved.

There is growing evidence that there exists a confluence of vascular and diffuse alveolar damage with SARS and possibly also COVID-19 disease. In some of the data with COVID-19 pneumonia,

McGonagle et al (24) have drawn attention to the similarities of blood vessel wall oedema, modest vessel wall immune cell infiltration, hyaline thrombosis and haemorrhagic change described earlier for patients with SARS, consistent with the observation that disseminated intravascular coagulation may develop late in COVID-19 disease. Consistent with this view Teuwen et al. (25) suggested that pulmonary endothelial cells (ECs) have been largely overlooked as a target in COVID-19, as the attending ECs altered vessel barrier function promotes a pro-coagulative vascular inflammatory state and an inflammatory cell infiltration. They also highlight the fact that SARS-CoV-2 binds to the ACE2 receptor impairing the enzyme that is the counterbalance for the vasoactive angiotensin II. The lung pathology COVID-19 disease displays microvascular thrombosis and haemorrhage with extensive alveolar and interstitial inflammation termed lung-restricted vascular immunopathology (24) . In the early stage is distinct from diffuse pulmonary intravascular coagulopathy. Cao and Li (26) also similarly highlighted the two hallmarks of critical patients with COVID-19 disease namely progressive inflammation and the trend to hypercoagulation. Furthermore, they draw attention not only to the inflammatory state as a trigger for coagulation, but endothelial cell disseminated intravascular coagulation, characterising the COVID-19 hypercoagulable state as displaying elevated D-dimer (a fibrin degradation product) and fibrinogen concentrations and prolonged prothrombin time (26) .

Previous studies have shown that in pulmonary hypertension there is a reduced ACE2 activity and that augmentation of ACE2 reduced oxidant and inflammatory markers as well as improving pulmonary hemodynamics (27) . Thirty years ago, our team established that in hypertensive blood vessels the endothelial cell mediated relaxation was impaired and this could be reversed with impairment of the prostanoid system or treatment with the ACEI captopril (28) . Collectively demonstrating a potential key role of the vascular endothelium in coagulation, inflammation and vasoconstriction and the capacity for abnormal function driven by the RAS. The RAS influence on the vasculature also extends to trophic factors. The neurotrophic peptide NGF is believed to be a pro inflammatory mediator in airways and promotes bronchial hyperresponsiveness, Freund-Michel et al. (29) . Of significance was our demonstration that the AT1R blocking agent losartan reversed the abnormal concentrations of NGF in blood vessels in hypertension (30) . fibrosis and pulmonary arterial hypertension (31) . Similarly, PAH is characterized by reduced ACE2 activity and the production of Angiotensin-(1-7) by ACE2 activating Mas receptors activation improves experimental models of PAH (27) .

As pointed out by Cao and Li 2020 (25) , SARS-CoV-2 can initially replicate in the upper respiratory track and later in the disease course replicate in the lower respiratory tract generating a secondary viremia with a subsequent attack on organ targets expressing ACE2. A dynamic consistent with the possibility outlined by Kreutz et al 2020 (11) and other groups that ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. From a repurposing standpoint there exists a strong target similarity with agents that promote RAS inhibition that involves blood vessel and vascular endothelial cell damage.

SARS-CoV-2 is an RNA virus and they have high mutation rates up to a million times higher than their hosts, and it is this high rate that enables the viruses to avoid host immunity and to achieve drug resistance (32) . From the standpoint of drug repurposing the selected drug should target, not the virus, but that aspect of the pathophysiology of COVID-19 that is tightly linked to the conserved mutational characteristics of the virus and its class. (35) . From that experimentation Wu suggested that the hot spot features were amongst the driving force for the convergent evolution of these two viruses. It follows that this would infer multiple binding opportunities for differing or mutated viruses but restricted to a common protein target. The targeted physiological process for driving pulmonary inflammation will be hard for a virus to abandon without significant penalty and can be viewed as conserved. From a repurposing standpoint that there exists a strong target similarity with agents that promote RAS inhibition and the common conserved site of the pathogenesis for COVID-

in treating the host across the cascade from prevention to the life-threatening consequences of other viral pathogenesis in COVID-19 disease. Cao and Li importantly summarise the clinical course of SARS-CoV-2 infection by dividing it into three phases: viremia phase, acute phase (e.g. with pneumonia) and severe or recovery phase (26) . From the standpoint of drug repurposing in COVID-19 we have adopted a similar approach, with particular focus on the severe phase, where the host system has switched on innate immune system, affecting inflammation. oedema, and vasconstriction. Our treatment focus in this phase is on RAS inhibition and (a) predisposition and age (b) predisposition with hypertension and co-morbidities (c) treatment and secondary infection and (d) intubation.

Increasing age has been shown to be a strong correlative factor with morbidity and mortality with COVID-19. As summarized by Shahid et al. studies have highlighted the relatively higher mortality rates in older adults (36) . While a variety of reasons may underpin this predisposition, it would appear that the RAS has a strong input to aging by way of mitochondrial function, specifically a strong relationship between free radicals, the mitochondria and aging, with excessive free radical production linked to dysregulation of RAS (37) . Key in this dysregulation is the angiotensin receptor AT1R and its linkage to NADPH and increased production of reactive oxygen 

Much has been written recently on the relationship between hypertension and COVID-19 disease.

Patients with severe COVID-19 are often older and with a history of hypertension as seen for example in 75% of patients that died in the COVID-19 pandemic in Italy had hypertension (12) .

As indicated earlier ACE2 is not only the target for SARS-CoV-2 but functionally balances the pulmonary and possibly vascular RAS/inflammation axis. Therefore, a potential increase in ACE2 mediated with antihypertensives, that act to inhibit RAAS, raised potential concerns with patients with COVID-19. There was insufficient data to determine whether these findings translated to humans and that clinical trials were underway to test these inhibitors in COVID-19 (42) . (63) , and no increased risk of COVID-19 causing infection requiring admission to hospital was seen with RAS agents (64, 65) .These results illustrate the importance of administrative/observational data consistent with the view that observational studies based on both big and small data sets are useful in understanding how to treat viral disease (4) . It also calls into question the need to keep doing observational studies of these agents when it is now reasonably compelling that RAS don't increase one's risk of COVID-19, don't increase mortality and in fact are very likely to reduce it significantly. In the time of a pandemic it is unclear why we are using off label agents with less data when we have for RAS agents where we know everything about the dose and the side effect profile -high potassium, allergic phenomena and low blood pressure all of which can actually be managed in the hospital setting.

What is of significance is the emerging understanding that cardiovascular disease like COVID-19. is a partially inflammatory state. In addition to the extensive discussion on hypertension and cardiovascular disease in COVID-19 there is an increasing body of evidence for a role of inflammation and immunity in hypertension and cardiovascular disease (51) . For example, there is a growing appreciation of the role of oxidative stress in the arterial wall, inflammatory infiltration, regulatory and interleukin 17 producing T-cells leading the development of hypertension (52) .

A role for inflammation in hypertension is documented as is a powerful role of inflammation in COVID-19 disease (14) . It is not surprising with this confluence that hypertension and related vascular disorders enhance susceptibility to this disease. It follows that from a repurposing standpoint a growing view would be not to abandon RAS inhibitors but rather explore their potential as repurposing agents in COVID-19.

Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury with a high mortality rate and pneumonia; infections such as COVID-19 and sepsis are predisposing factors together with aspiration (summarised in 18). Twenty years before COVID-19, it was suggested that the RAS had a role in the pathogenesis of ARDS and demonstrated that angiotensin converting enzyme insertion/deletion polymorphism was associated with susceptibility and outcome in ARDS (53) . This has been shown in human data with COVID-19, mortality disproportionally affecting Blacks who commonly have DD mutation. Even back in 2002 this team suggested that that ACE inhibitors may lower the risk of developing ARDS or reduce the severity of the disease. Subsequently in animal experiments in acute lung injury angiotensin II is upregulated and mediates acute lung failure by way of the AT1 receptor and that ACE2 and the AT2 receptor are protective against this injury (17) . This article is protected by copyright. All rights reserved.

the ARB losartan improved animal survival and ameliorated acute lung injury (6) .

Based on a retrospective cohort non COVID-19 pneumonia study Mortensen et al 2012 (54) examined the influence of statins and inhibitors of the RAS on outcomes. They concluded that statins and to a lesser extent ACE inhibitors and ARBs improved these outcomes. The potential benefits of the pulmonary effects of ARBs aware seen, and they speculated that having increased ACE2 expression with pre-existing ARB treatment may be of benefit in the course of SARS-CoV-2 infection (14) . In a similar fashion in a recent review on COVID-19 (12) concluded that with patients with lower respiratory tract infections ACEIs and ARBs may be associated with improved outcomes. 

The key question here is not just around the evidence that the agents that inhibit the RAS improve patient outcomes in COVID-19 disease but at what doses -both for efficacy and for toxicity.

Over the last several months in 2020 we are aware of at least four clinical observational based studies, (43) (44) (45) (46) all derived from medical records of patients hospitalised for COVID-19. As indicated above these studies did not indicate a deterioration of patients with RAS inhibition and conversely to varying extents an improvement in outcomes when compared to patients with COVID-19 disease not treated with RAS inhibitors. By inference these patients were likely being treated prior to hospitalisation for hypertension or diabetes on the standard drug regimens. Based on observational data there would be an argument to explore further the possibility of a new indication for RAS inhibitors as repurposed drugs in COVID-19.

The specific question of interest here is whether there is evidence that RAS agents are effective at doses below the approved Cmax in attenuating pulmonary responses and preventing or reversing the aberrant inflammatory pathophysiology. This is also important dosing knowledge to reduce toxicity.

In a comprehensive review on repurposing (11) potential differences in dosing amounts and schedules in the area of repurposing. Our experience has indicated that if the ED50 for the new indication for the repurposed drug is equal to or less than the Cmax achieved by the drug in registered dosing schedules for its original indication then dosing issues become less complex and the arguments for registration of the repurposed drug for a new indication much easier. The point being that the bioavailability, toxicology and pharmaco-surveillance of the drug at that dose, is well established as part of the original drug approval process, albeit the disease being treated is different. This latter point may introduce issues around dose-response and also dose-toxicity, but they can be surveyed from an a priori basis rather than from no knowledge. This article is protected by copyright. All rights reserved.

By inference in the studies based upon observational data described immediately above; Section 4a; the COVID-19 patients were likely being treated prior to hospitalisation for hypertension or diabetes on the standard drug regimens. If that were so then it could be assumed that the RAS inhibitors would have been employed at or below their approved Cmax obtained from the top of the dosing range for the RAS inhibitors.

As there is no human information to date on these preclinical aspects, we need to analyse known pharmacological data from cellular systems and animals; and use supporting data from human studies of other viruses that cause ARDS in a pathophysiological process resembling COVID-19.Based upon the observational data there would be an argument to explore further the possibility of a new indication for RAS inhibitors as repurposed drugs in COVID-19 initially within the existing approved Cmax of the drugs.

We need to know the historical safety of proposed RAS inhibitors in exploring their potential role as repurposed drugs for treating COVID-19. Losartan, telmisartan, olmesartan (and additional AT1R antagonists) have been widely applied in the clinic since the 1990s for control of hypertension, diabetes and some kidney disorders, and are known as safe drugs that are rarely implicated in adverse drugs events (58) (59) .

Based on historical safety experience data there would be an argument to explore further the possibility of a new indication for RAS inhibitors as repurposed drugs in COVID-19.

The importance of the host response in infectious disease has been highlighted very recently including the suggestion that ARBs and statins, both very cheap, off patent and in our pharmacies currently could be evaluated to improve outcomes including survival in COVID-19 patients (5). This approach builds upon the pioneering earlier (4), treating of the host concept, based upon an understanding that a beneficial clinical phenotype has been observed with a treatment and this can be employed for the purpose of treating the host.

The approach brings together three concepts; namely the value of therapeutics in stabilizing patients prior to subsequent interventions, repurposing therapeutics for new indications and potential of treating the host. During this review the following became evident:  There is a need to comprehensively determine if there exists an alignment of the proposed repurposed drug with the known pathophysiology of the viral infection. In the case of RASI what is remarkable is the interplay between an existing predisposition to RAS induced inflammation with an overlay of severe RAS dysregulation with COVID-19 disease.

 The fundamental importance of observational (administrative)data as a pathfinder source of information from which to select candidate drugs for evaluation in a repurposed context.

 The importance to adhere to the principals of repurposing as they relate to dose and safety.

We have described a framework for treating the host with repurposed drugs and illustrated its use using RAS inhibitors. We would caution that even though there exists observational data highlighting a potential protective effect of RAS inhibition consistent with a pathophysiological alignment this outcome may still be due to chance Therefore, based on our analysis we believe a clinical trial for RAS inhibitors would be justified. However noting that also that at least eight trials of this type have already been registered, and we have quality observational data on infection rate, severity of disease, admission to ICU and death which is at least non inferior, and in some studies suggesting significant mortality benefit, together with plausible mechanistic data with currently available doses, and a side effect profile that is well known and able to be managed, in line with critical trial design thinkers emerging in this pandemic, use in clinical practice could be justified (66, 67) .This reinforces the concurrent move in the pharmacology world to delineating the treatment of the host from treatment and elimination of the infective agent to treating the host, as out lined and pioneered by David Fedson many years ago.

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers

Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola

Observational studies help us understand how to treat pandemic influenza and other emerging virus diseases

Hiding in plain sight: an approach to treating patients with severe COVID-19 infection

Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse

Buying time: Drug repurposing to treat the host in COVID-19H

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

The Damage-Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases

Drug repurposing: progress, challenges and recommendations

Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

European Society of Hypertension COVID-19 Task Force Review of Evidence Cardiovascular Research (2020) 0, 1-12 REVIEW

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Response to the emerging novel coronavirus outbreak

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

Mast cell renin and a local renin-angiotensin system in the airway: Role in bronchoconstriction PNAS

Mast cells in human airways: the culprit?

All because of the mast cell: blocking the angiotensin receptor-1 should be better than inhibiting ACE (theoretically) Cardiovascular Research

Angiotensin-converting enzyme in innate and adaptive immunity

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

COVID-19: the vasculature unleashed

Research highlight COVID-19: towards understanding of pathogenesis Cell Research

A potential therapeutic role for Angiotensin Converting Enzyme 2 in human pulmonary arterial hypertension

The Influence of Chronic Captopril Treatment and Its Withdrawal on Endothelium-Dependent Relaxation. Blood Press

Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension

The influence of the renin angiotensin system on abnormal expression of nerve growth factor in the spontaneously hypertensive rat Volume22, Issue6-7July 1995 Pages 478-480

The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitorslessons from available evidence and insights into COVID-19

PERSPECTIVES Integrative Cardiovascular Physiology and Pathophysiology COVID-19, ACE2, and the cardiovascular consequences

A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses

COVID-19 and Older Adults: What We Know

The impact of age-related dysregulation of the angiotensin system on mitochondrial redox balance

Evidence for a mitochondrial angiotensin-(1-7) system in the kidney

Exosome-Mediated Transfer of ACE2 (Angiotensin-Converting Enzyme 2) from Endothelial Progenitor Cells Promotes Survival and Function of Endothelial Cell

Proteomic analysis of up-regulated proteins in human promonocyte cells expressing severe acute respiratory syndrome coronavirus 3C-like protease Proteomics

Enalapril and losartan attenuate mitochondrial dysfunction in aged rats

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With

Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Continued in-hospital ACE inhibitor and ARB Use in hypertensive COVID-19 patients is associated with positive clinical outcomes

Overcoming barriers: the endothelium as a linchpin of coronavirus disease 2019 pathogenesis?

Hemodynamic impact of cardiovascular antihypertensive medications in patients with sepsis-related acute circulatory failure. Shock

ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID-19 infection in a multi-site UK acute Hospital Trust

Impact of angiotensinconverting enzyme inhibitors and statins on viral pneumonia PROC

Hypertension as an autoimmune and inflammatory disease Hypertension Research

Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes

Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study Korean J Crit Care Med

Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model

Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome Intensive Care Medicine Experimental

Telmisartan: A review of its pharmacodynamic and pharmacokinetic properties

Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension

In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19

Effect of antihypertensive medications on sepsis-related outcomes: a population-based cohort study

Preadmission antihypertensive drug use and sepsis outcome: impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Shock

Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19. medRxiv

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

Optimizing the trade-off between learning and doing in a pandemic

Observational research, randomised trials, and two views of medical science

This article is protected by copyright. All rights reserved.